Jacobson Allan Steven, an insider at PTC Therapeutics Inc (PTCT), sold 19,389 shares of the company on November 24, 2025, at a price of $83.38 per share, totaling $1.62 million. Following this transaction, he retains 19,389 shares of the company.
PTC Therapeutics, headquartered in Warren, New Jersey, focuses on developing and commercializing medicines for rare disorders. The company’s market capitalization stands at $6.9 billion, with a trailing P/E ratio of 9.21 and an EPS of 8.53. PTC has two main products, Translarna (ataluren) and Emflaza (deflazacort), aimed at treating Duchenne muscular dystrophy (DMD), as well as Upstaza, a gene therapy for AADC deficiency. The company is preparing for upcoming earnings reports, with estimates of $-0.54 EPS and $222.6 million in revenue for August 5, 2026.
Insider transactions like this one are reported to the SEC, providing transparency regarding executives' views on their company’s stock. While such sales can indicate various personal or financial motivations, they should not be the sole factor in investment decisions. Investors are advised to consider broader patterns of insider activity across multiple individuals and timeframes to gain a more comprehensive understanding of market sentiment.